University of Georgia Research Foundation Inc

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Biology Centre Cas, V.v.i.

Michael Strand

Ivo M Francischetti

Donald Champagne

Michail Kotsyfakis

Hitoshi Tsujimoto

Provided herein are methods of producing a genetically modified cell by introducing a polydnavirus delivery construct to a target cell. The polydnavirus delivery construct can comprise an exogenous nucleic acid to form a genetically modified cell comprising the exogenous nucleic acid. Also provided are polydnavirus delivery constructs comprising an exogenous nucleic acid, as well as polydnavirus virions and genetically modified cells comprising the same. Further provided are in vitro methods of identifying a transformed cell. The methods comprise introducing a vector comprising a nucleotide sequence encoding a glc polypeptide to an adherent cell and cultivating the cell under conditions that allow for the expression of the glc polypeptide. Expression of the glc polypeptide results in a transformed cell that is identified by a loss of adherency.

Polydnavirus delivery constructs

The present invention includes a novel protein, also referred to herein as simukunin, that inhibits the function of several physiologically important enzymes. Simukunin is a potent inhibitor of the blood coagulation cascade, inhibiting Factor Xa and functioning as an efficient anticoagulant. Simukunin also inhibits the serine proteases elastase and cathepsin and demonstrates anti-inflammatory properties. Also included are methods of making and using simukunin.

Simukunin

Growing community of inventors

Athens, GA, United States of America

Michael Strand